



Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Patrick E. Garrett Jeffrey T. Helvey Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Brian J. Del Buono Mark Fox Evens Edward W. Yee Vincent L. Capuano Origil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Daniel A. Klein Jason D. Eisenberg Michael D. Specht Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longsworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Anbar F. Khal
Michelle K. Holoubek
Marsha A. Rose
Young Tang
Christopher J. Walsh

W. Blake Coblentz-James J. Pohl* John T. Haran Mark W. Rygiel Kevin W. McCabe Michael R. Malek* Registered Patent Ager Karen R. Markowicz Matthew J. Dowd Katrina Yujjan Pei Qua Bryan L. Skelton

Registered Patent Agents « Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Bryan L. Skelton Bryan L. Skelton Kobert A. Schwartzman Victoria S. Rutherford Simon J. Elliott Julie A. Heider Mita Mukherjee Scott M. Woodhouse Liliana Di Nola-Baron Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland * Admitted only in Virginia • Practice Limited to Federal Agencies

February 6, 2007

WRITER'S DIRECT NUMBER: (202) 772-8529 INTERNET ADDRESS: LVOGEL@SKGF.COM

Art Unit 1637

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/719,978; Filed: November 24, 2003

For: Process for Purification of Plasmid DNA

Inventors: BUDAHAZI *et al.*Our Ref: 1530.0550001/EKS/LAV

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Second Supplemental Information Disclosure Statement Under 37 C.F.R § 1.97(c);
- 2. Form PTO/SB/08A listing 3 cited documents (AN4 AP4) (1 page); and
- 3. Copies of the 3 cited documents (AN4 AP4); and
- 4. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC.: 1100 New York Avenue, NW: Washington, DC 20005: 202.371.2600 f 202.371.2540: www.skgf.com

Commissioner for Patents February 6, 2007 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

logel

Laura A. Vogel

Attorney for Applicants Registration No. 55,702

LAV/amz Enclosures

622775_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re application of:

Budahazi et al.

Appl. No.: 10/719,978

Filed: November 24, 2003

For: Process for Purification of Plasmid

DNA

Confirmation No.: 1745

Art Unit:

1637

Examiner:

STRZELECKA, Teresa E.

Atty. Docket: 1530.0550001/EKS/LAV

Second Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(c)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Form, PTO/SB/08A, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on March 17, 2005, in connection with the above-captioned application.

Copies of AN4 to AP4 are submitted.

Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.

I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1). Therefore, no statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Laura A. Vogel

Attorney for Applicants Registration No. 55,702

Date: Fely 6, 2007

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

619969v1

Equivalent of Form PTO/SB/08A (09-06)

Approved for use through 03/31/2007. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO Complete if Known 10/719,978 Application Number SECOND SUPPLEMENTAL Filing Date November 24, 2003 INFORMATION DISCLOSURE FEB 06 First Named Inventor BUDAHAZI, Gregg STATEMENT BY APPLICANT PATE TRADE Art Unit 1637 (Use as many sheets as necessary) **Examiner Name** STRZELECKA, Teresa E. Sheet Attorney Docket Number 1530.0550001/EKS/LAV of

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,
Initials*	No.1	Number-Kind Code ² (If Known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages
		Transcer Tend Code			or Relevant Figures Appear
					····
					The same with the Property of the
				Rught African American mengangkan mendilan	The state of the s
				Tanana and a state of the state	error er la lier virtige
				10.15	
			6.1 1		· · · · · · · · · · · · · · · · · · ·
					- · · · · · · · · · · · · · · · · · · ·
			41 · 14 · 14 · 14 · 14 · 14 · 14 · 14 ·		
	, .				
· · · · · · · · · · · · · · · · · · ·					1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
			**		
17 11 1					
;				* i. · · ·	3 10 10 10 10
• •			. ,		
	· · · · ·		L		
			FOREIGN PATENT I		
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where
		Country Code ³ Number ⁴ Kind Code ⁵ (if know	n).		Relevant Passages or Relevant Figures
		,			Appear 7
:	AN4	WO 01/46215 A1	06/28/2001	Merck & Co., Inc.	
	AO4 ' '	WO 96/02658 A1	02/01/1996	Merck & Co., Inc.	
	AP4		06/17/1999	Génzyme Corporation	
		110 33123032	"	Genzyme Corporation	,
		•			
0					_
					-
- :			· · · · · · · · · · · · · · · · · · ·	 	
•				<u> </u>	
		<u> </u>			<u></u>
Examine	.		•	Date	•
Signaturė				Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.